Johnson & Johnson has temporarily paused the rollout of its Varipulse heart device in the U.S. to investigate four reported stroke events.
The company emphasizes patient safety and is working diligently to resolve the issue while continuing commercial activities outside the U.S.
Johnson & Johnson will pause US rollout of its Varipulse heart device while it investigates a series of four reported stroke incidents associated with use of the product.
The announcement by J&J on 5 January, 2025, is cited as “an abundance of caution” in pursuit of patient safety as it addresses the issue in question.
Varipulse creates a system employing pulsed-field ablation in the treatment of drug-refractory paroxysmal atrial fibrillation, the commonest form of abnormal heart rhythm.
The technology was cleared by the FDA—which regulatory bodies approved in November 2024—to add substantially to an otherwise limited toolkit available for the treatment of cardiac disorder. The technology would enhance both safety and effectiveness in treating disorders of the heart rhythm.
J&J, in turn, said, “We are working diligently to complete the investigation according to our medical safety processes and resume the U.S. External Evaluation.”
This external evaluation is a limited release intended to gather user experiences from health professionals on the new technology before any broader release can be considered.
It forms the backbone of knowing how devices really perform at the clinical level in the real world and that risks, if any, would be well thought of.
Immediate reaction
J&J stock fell 3% in afternoon trading, while those of Boston Scientific and Medtronic rose 5% and 4%, respectively. Such immediacy speaks much about the competitive nature in the industry of medical devices, where any news on product safety could well be one of the prime factors affecting the investors’ confidence and dynamicity in the market.
Due to this, while the pause was put on in the U.S., J&J made sure to reassure stakeholders that “commercial activity and cases outside the United States would not be affected by the pause.”
The company will keep being transparent over this investigation and wants updating of information when available. This is a clear case for vigilance during medical device development and continuing commitment to safety in healthcare innovation.
